TOP10 reimbursement value in Poland – December 2024

?? Updated December 2024 #DGL bulletin data

?? Market Overview & Reimbursement Trends

By the end of 2024, the total cumulative reimbursement has reached PLN 24.2 billion, reflecting an increase of PLN 4.2 billion compared to the same period last year.

?? Top Whole Market Performers: The ranking of the top three reimbursed products remains unchanged, with Keytruda maintaining its leading position, achieving a cumulative reimbursement of PLN 942 million — a remarkable 49% year-over-year growth. Meanwhile, Lynparza has climbed to 6th place, with total reimbursements amounting to PLN 285 million, marking a 35.2% growth year-over-year. Collectively, the TOP10 brands account for 16.4% of the total market share.

In the foodstuff category, the TOP10 brands dominate with an 88% market share, with Bebilon Syneo securing the leading position.

?? Drug Programmes & Outpatient Market:

• Within drug programmes, Lynparza has moved up to 4th place, experiencing a 35% growth in year-over-year reimbursement.
• In the outpatient segment, Ozempic has surged to 4th position, posting an exceptional 103% growth in reimbursement, with a cumulative total of PLN 186 million for 2024. Meanwhile, Roswera has made its debut in the TOP10 for medical products, securing 10th place.

?? Overall Market Growth: By the end of 2024, the cumulative reimbursement for the TOP10 brands has approached PLN 4 billion. The overall market has expanded by PLN 906 million year-over-year, representing a robust growth rate of 29.4%.

We encourage you to independently analyze all the data using our PowerBI IDA report.